Statin loading before percutaneous coronary intervention: proposed mechanisms and applications

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Statin therapy is known to reduce cardiovascular events in coronary artery disease patients.
• Emerging evidence highlights LDL-independent actions of statins, including modulation of endothelial function, inflammation, and thrombosis.
• Periprocedural myocardial infarction and contrast-induced nephropathy are significant complications following percutaneous coronary intervention (PCI), linked to inflammatory pathways.

Purpose of the Study:

• To evaluate the efficacy of short-term, high-dose statin pretreatment in mitigating periprocedural complications of PCI.
• To assess the impact of statin therapy on myocardial damage and contrast-induced nephropathy in patients undergoing PCI.

Main Methods:

• Review of randomized studies and clinical evidence on statin therapy in patients undergoing PCI.
• Analysis of data concerning short-term statin pretreatment, acute high-dose loading, and reloading strategies.
• Examination of outcomes related to periprocedural myocardial infarction and contrast-induced nephropathy.

Main Results:

• Short-term statin pretreatment significantly reduces periprocedural cardiac marker release in patients undergoing PCI.
• High-dose atorvastatin loading prevents myocardial damage in acute coronary syndromes undergoing early PCI.
• Statin therapy at the time of PCI decreases contrast-induced nephropathy incidence and improves 30-day major adverse cardiac event rates.

Conclusions:

• Short-term, high-dose statin administration ('upstream therapy') is beneficial for all patients undergoing PCI.
• This strategy effectively reduces periprocedural myocardial infarction and contrast-induced nephropathy.
• Statin therapy offers significant advantages beyond LDL reduction in the context of interventional cardiology procedures.